Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Mo Jain_2024
VIEWPOINTS

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Shots:  Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots  Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome  While highlighting Sapient’s…
April 16, 2024

Read more

Biopharm Top 20 2023
TOP 20

Top 20 Biopharma Companies of 2024

Shots: Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…
April 11, 2024

Read more

VIEWPOINTS_Kari Wong_2024
VIEWPOINTS

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Shots:   Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots    The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…
April 8, 2024

Read more

Insights+ Key Biosimilars Events of March 2024
INSIGHTS+

Insights+ Key Biosimilars Events of March 2024

Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    During March, Sandoz received the US FDA’s approval for Wyost & Jubbonti.…
April 3, 2024

Read more

VIEWPOINTS_Ahsan Arozullah_2024
VIEWPOINTS

A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah

Shots:  Transformative combination therapies add wonder to oncology therapeutics now and then. Dr. Ahsan Arozullah, in another engaging conversation with PharmaShots, talks about Padcev + Keytruda therapy for adult patients suffering from locally advanced or metastatic urothelial cancer (la/mUC)  Ahsan shares insights from the P-III (EV-302) trial based on which the FDA accepted Padcev +…
April 2, 2024

Read more

New Drug Designations - February 2024
INSIGHTS+

New Drug Designations – February 2024

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, and EC. This month’s report includes designations allotted to 13 small molecules, 20 biologics, and 2 devices  SN Bioscience’s SNB-101 received ODD from the US FDA for the treatment of pancreatic cancer based on preclinical results. It…
March 28, 2024

Read more

Load more